However, implication of NGAL in a myriad of processes such as acute kidney injury, heart failure, and stable CAD, as well as inconsistence in data regarding prediction of clinical outcomes reduces its chance for establishment as a biomarker of plaque vulnerability [89,93,94]. This evidence concerns the gene LCN2 and coronary artery disorder.